	US 11,835,519 B2
	Autoantibodies to Septin-7 and diagnosis of neurological disease
Ramona Miske, Luebeck (DE); Madeleine Scharf, Selmsdorf (DE); Lars Komorowski, Ratzeburg (DE); Yvonne Denno, Luebeck (DE); Stefanie Hahn, Reinfeld (DE); Christiane Radzimski, Reinfeld (DE); Mandy Unger, Hamburg (DE); Andrew McKeon, Rochester, MN (US); Sean Pittock, Rochester, MN (US); Thomas Kryzer, Mantorville, MN (US); Vanda Lennon, Rochester, MN (US); and Josephe Honorat, Brooklyn, NY (US)
Assigned to EUROIMMUN Medizinische Labordiagnostika AG, Luebeck (DE); and Mayo Foundation for Medical Education and Research, Rochester, MN (US)
Filed by EUROIMMUN Medizinische Labordiagnostika AG, Luebeck (DE); and Mayo Foundation for Medical Education and Research, Rochester, MN (US)
Filed on Dec. 8, 2020, as Appl. No. 17/114,984.
Claims priority of application No. 19217147 (EP), filed on Dec. 17, 2019.
Prior Publication US 2021/0181196 A1, Jun. 17, 2021
Int. Cl. G01N 33/564 (2006.01); A61K 38/17 (2006.01)

CPC G01N 33/564 (2013.01) [A61K 38/1709 (2013.01); G01N 2333/46 (2013.01); G01N 2800/28 (2013.01)]

13 Claims

1. A method, comprising:

detecting, in a sample from a patient, an autoantibody binding to Septin-7, and an absence of the autoantibody binding to one or more of Septin-3, Septin-5, Septin-6, or Septin-11,

wherein the patient has or is suspected of having a disease, wherein the disease is selected from the group consisting of paraneoplastic neurological syndrome (PNS), neuropathy, encephalopathy, encephalitis, encephalomyelopathy, myelopathy, episodic ataxia, bilateral carpal tunnel syndrome, and lumbosacral polyradiculopathy, or

wherein the disease is a tumor selected from the group consisting of ovarian cancer, breast adenocarcinoma, Non-Hodgkin lymphoma, carcinoid, myelodysplastic syndrome, and carcinoid of the lung.